Wolfe Research analyst Andy Chen lowered the price target on Viridian Therapeutic (NASDAQ: VRDN) to $29.00 (from $37.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE